NCT01640951: A reported trial by Novartis Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01640951 |
|---|---|
| Title | A Multicenter, Double-blind and Open Label, 4 Year Extension Study of Subcutaneous Secukinumab in Prefilled Syringes, Assessing Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Treated With Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 16, 2012 |
| Completion date | May 4, 2017 |
| Required reporting date | May 4, 2018, midnight |
| Actual reporting date | April 23, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |